500 Old Connecticut Path
About BergBerg, is a biopharmaceutical company with a research focused on understanding how alterations in metabolism relate to disease onset. We have uncovered key insight into metabolic control factors and namely into underlying elements in the Warburg Hypothesis. The company has a deep pipeline of early- stage technologies in CNS diseases and metabolic diseases that complement its late-stage clinical trial activity in cancer and prevention of chemotoxicity. Armed with the use of the Berg Interrogative Biology™ discovery platform that translates biological output into viable therapeutics and a robust biomarker library, Berg is poised to realize its pursuit of a healthier tomorrow.
Berg's application of machine-learning (Artificial Intelligence) in biology and medicine allows for a combination of systems biology and systems engineering leading to well defined answers on human health. The Berg Interrogative Biology™ platform integrates molecular data directly from a patient with clinical and demographic information to learn predictive patterns. The platform has the potential to provide the physician with actionable information to recommend efficient and safe treatment pathways, insurance companies with health economics analyses to develop more relevant formulary and governments with a data ecosystem for financial modeling of healthcare needs of the population.
For additional information, please visit www.berghealth.com.
37 articles with Berg
BERG Presents First-In-Kind Data Using Its Bayesian AI-Driven Interrogative Biology® Technology To Map Underlying Biology Of Patient Responses In Advanced Solid Tumor Trial Of BPM31510
Early phase study of BPM31510 demonstrates BERG's Interrogative Biology® platform can identify the molecular basis of efficacy and adverse events, offering critical insights for drug late-stage development from analyses of longitudinal patient samples
BERG Presents Key Findings From Two Important Clinical Initiatives At The 2019 ASCO Annual Meeting: BERG's Final Phase 1 Results For BPM 31543 In Chemotherapy-Induced Alopecia And A Clinical Study
BERG announced the presentation describing key results from two major clinical initiatives at the American Society of Clinical Oncology Annual Meeting in Chicago, being held from May 31th – June 4th.
BERG Presents Novel Mechanism Underlying BPM 31510 in Glioblastoma and Identification of Prostate and Pancreatic Cancer Biomarkers at 2019 AACR Meeting
BERG announced four presentations at the American Association for Cancer Research Annual Meeting in Atlanta, being held from March 29th - April 3rd.
BERG Presents Clinical Target Validation Data for the Treatment of Parkinson's Disease and Novel Mechanism of Action in Neurological Disorders at Neuroscience 2018
BERG LLC today announced four abstracts showcasing the value of its Back to Biology™ approach in identifying disease signatures and mechanisms of Parkinson's disease (PD) and other neurological disorders were presented at the annual meeting of the Society for Neuroscience (SfN) in San Diego, California, Nov. 3-7, 2018.
Berg Analytics, a division of BERG LL today announced the acceptance of a poster for presentation describing data-driven predictive modeling for septic shock at the American Medical Informatics Association (AMIA) 2018 Annual Symposium being held November 3-7, 2018 in San Francisco.
Steven Hamburger, Ph.D. appointed as Vice President, Regulatory Affairs and Laura Mei appointed as Vice President, Clinical Operations.
BERG, LLC presented in a poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting.
BERG Announces FDA Orphan-Drug Designation of BPM 31510 for the Treatment of Patients with Epidermolysis Bullosa
Epidermolysis Bullosa is a rare, pervasive and debilitating connective tissue disorder for which there is currently no FDA-approved treatment or cure.
New Research Partnership Will Leverage BERG Interrogative Biology Platform and Identify Novel Biomarker and Targets for Diagnosis and Treatment of Alzheimer's Disease
Under the terms of the collaboration, MGH and BWH will provide access to a longitudinal collection of clinically annotated patient-derived biospecimens from the Harvard biomarker study.
Berg Broadens Relationship With The Department Of Defense (DoD) Center For Prostate Disease Research With New Predictive Biomarker Test For Prostate Cancer
Berg Presents Key Clinical Data At ESMO 2017 On BPM 31510 For Advanced Pancreatic Cancer Patients And BPM 31543 For Preventing Hair-Loss In Patients Treated With Chemotherapy
Berg Forms Research Collaboration With AstraZeneca PLC To Identify New Therapeutic Targets To Treat Neurological Disorders Such As Parkinson's Disease
Berg Announces New Partnership With Debra Of America To Tackle Epidermolysis Bullosa-A Rare Genetic Tissue Disorder
Berg Announces BPM 31510 Data Presentations At 2017 AACR In Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers And Novel Prostate Cancer Biomarker Panel
Berg Release: New Data Published In Nature Medicine From Joslin Diabetes Center Demonstrates The Importance Of Interrogating Human Biology
Berg Initiates Phase I/II Monotherapy Trial Of BPM 31510-IV In Patients With Glioblastoma Multiforme (GBM)
Berg Release: Company Enters Into Multi-Year Agreement With Becton, Dickinson and Company For Next-Generation Analytics In Healthcare IT
Berg Presents Data Uncovering A Novel Contributor To Parkinson's Disease At Society For Neuroscience 2016 Meeting
Berg Expands Research Collaboration With Department Of Defense And Walter Reed National Military Medical Center To Advance Precision Medicine For Breast Cancer Patients